Roche Revenue Breakdown & Fiscal Growth

Roche's financial performance over the past decade has been shaped by two major forces operating in opposite directions: the biosimilar erosion of its legacy oncology biologics franchise, which peaked collectively at approximately CHF 20 billion in annual revenue before declining sharply from 2018 onward, and the simultaneous growth of the next-generation portfolio, which has progressively replaced the eroded revenue with medicines that are clinically differentiated and therefore more defensible. Group sales reached CHF 58.7 billion in 2023, down from a COVID-elevated peak of approximately CHF 63 billion in 2021 as diagnostics revenue normalised following the pandemic-driven surge. The underlying trend—stripping out COVID diagnostics volatility—shows a business that has managed the biosimilar cliff more successfully than investors feared in 2017, when the pending loss of exclusivity for Herceptin, Avastin, and Rituxan prompted widespread analyst concern that Roche would face a sustained multi-year revenue decline comparable to the patent cliffs that devastated other major pharmaceutical companies in the 2010–2015 period. The pharmaceuticals division's revenue evolution illustrates both the severity of the biosimilar impact and the effectiveness of the portfolio replacement strategy. Herceptin revenue fell from approximately CHF 7 billion at its 2018 peak to below CHF 2 billion by 2022 as biosimilar versions launched by Samsung Bioepis, Mylan, Pfizer, and others captured substantial share across European and US markets. Avastin and Rituxan followed similar trajectories. Combined, these three products lost approximately CHF 15 billion in annual revenue over a four-year period—a headwind of extraordinary magnitude that Roche absorbed while maintaining overall sales stability through the growth of Ocrevus (reaching over CHF 6 billion in annual sales by 2023), Hemlibra (over CHF 4 billion), Tecentriq, Perjeta, and the newer launches. Core earnings per share—Roche's preferred non-GAAP profitability measure, which excludes amortisation of intangible assets and other items—have been sustained at CHF 16–18 per share through the transition period, a performance that reflects both the operating leverage of the pharmaceutical model and the pricing discipline that management has maintained on the new product portfolio. The dividend—which Roche has increased for 37 consecutive years as of 2024, making it a member of the elite group of Swiss dividend aristocrats—has been a consistent signal of management confidence in the underlying cash generation capability of the business. Capital allocation at Roche reflects the dual demands of sustaining the R&D investment that funds the next generation of medicines and returning capital to shareholders through dividends and, occasionally, share buybacks. R&D investment consistently represents approximately 20% of group sales—approximately CHF 12 billion annually—a figure that reflects both the cost of the clinical trial programmes required to support the existing portfolio's label expansions and the investment in the next generation of molecules across the pipeline. The R&D investment is substantially higher as a percentage of pharmaceutical division sales, where it more accurately reflects the innovation intensity of a business that depends on a continuous supply of new medicines to replace those lost to patent expiry and biosimilar competition.